Qube Research & Technologies LTD Rain Therapeutics Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RAIN
# of Institutions
3Shares Held
122KCall Options Held
0Put Options Held
0About Rain Therapeutics Inc.
- Ticker RAIN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,837,400
- Description
- Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...